BSX

Healthcare Medical Devices

Boston Scientific Corporation

$42.15
-0.27 -0.65% today Live

Price History

Not enough data
Price chart data
DatePrice
Oct 6, 2026, live at 2:48 PM ET42.15

Key Stats

Market Cap
61.08B
Avg Volume
19.64M
P/E (TTM)
17.06
EPS
$2.47
52W High
$105.65
52W Low
$41.94
Div. Yield
0.0%

Analyst Ratings

Buy
7
Str Buy
18
Buy
6
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
12.38
P/B Ratio
2.45
P/S Ratio
2.91
EV/EBITDA
12.92
EV/Revenue
3.51
PEG Ratio
0.60

Margins

Gross Margin 69.2%
Operating Margin 22.9%
Net Margin 17.5%
EBITDA Margin 27.2%

Growth & Returns

Revenue Growth (YoY)
7.5%
Earnings Growth (YoY)
15.1%
Earnings Growth (QoQ)
13.8%
Return on Equity
15.3%
Return on Assets
6.2%

Liquidity & Leverage

Current Ratio
1.24
Quick Ratio
0.56
Debt / Equity
0.50
Total Cash
539.00M
Total Debt
12.62B

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

www.bostonscientific.com